| Pretransplant ruxolitinib: key points |
| • Response to ruxolitinib is associated with favorable outcomes after HSCT. |
| • Patients failing ruxolitinib therapy should be considered as candidates for HSCT within 6–12 months, if suitable. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.